

Mark S Todtenkopf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9462395/publications.pdf>

Version: 2024-02-01

21
papers

1,815
citations

623734

14
h-index

839539

18
g-index

22
all docs

22
docs citations

22
times ranked

1783
citing authors

#	ARTICLE	IF	CITATIONS
1	Antidepressant-Like Effects of μ -Opioid Receptor Antagonists in the Forced Swim Test in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305, 323-330.	2.5	436
2	Depressive-Like Effects of the μ -Opioid Receptor Agonist Salvinorin A on Behavior and Neurochemistry in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 316, 440-447.	2.5	340
3	Effects of μ -opioid receptor ligands on intracranial self-stimulation in rats. <i>Psychopharmacology</i> , 2004, 172, 463-470.	3.1	248
4	Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. <i>Molecular Psychiatry</i> , 2019, 24, 576-587.	7.9	130
5	A cross-study meta-analysis and three-dimensional comparison of cell counting in the anterior cingulate cortex of schizophrenic and bipolar brain. <i>Schizophrenia Research</i> , 2005, 73, 79-89.	2.0	108
6	Distribution of glutamate decarboxylase65 immunoreactive puncta on pyramidal and nonpyramidal neurons in hippocampus of schizophrenic brain. , 1998, 29, 323-332.		93
7	The Kappa-Opioid Agonist U69,593 Blocks Cocaine-Induced Enhancement of Brain Stimulation Reward. <i>Biological Psychiatry</i> , 2008, 64, 982-988.	1.3	79
8	Differential distribution of tyrosine hydroxylase fibers on small and large neurons in layer II of anterior cingulate cortex of schizophrenic brain. , 1997, 25, 80-92.		75
9	GluR5,6,7 subunit immunoreactivity on apical pyramidal cell dendrites in hippocampus of schizophrenics and manic depressives. <i>Hippocampus</i> , 2001, 11, 482-491.	1.9	72
10	Brain Reward Regulated by AMPA Receptor Subunits in Nucleus Accumbens Shell. <i>Journal of Neuroscience</i> , 2006, 26, 11665-11669.	3.6	64
11	<p>A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2559-2569.	2.2	42
12	Contribution of drug doses and conditioning periods to psychomotor stimulant sensitization. <i>Psychopharmacology</i> , 2006, 185, 451-458.	3.1	25
13	Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone. <i>Pharmacology Biochemistry and Behavior</i> , 2008, 89, 515-522.	2.9	24
14	Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates. <i>Journal of Psychopharmacology</i> , 2019, 33, 1303-1316.	4.0	23
15	PRECLINICAL STUDY: Route of administration affects the ability of naltrexone to reduce amphetamine–potentiated brain stimulation reward in rats. <i>Addiction Biology</i> , 2009, 14, 408-418.	2.6	17
16	Using a rate-frequency curve method to assess the rewarding properties of morphine in the intracranial self-stimulation paradigm in rats. <i>Journal of Neuroscience Methods</i> , 2010, 189, 75-79.	2.5	14
17	Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 100, 530-537.	2.9	12
18	An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 2885-2904.	2.2	9

#	ARTICLE	IF	CITATIONS
19	Evaluation of samidorphan, a μ -opioid antagonist, in a drug discrimination assay in rats. Drug Development Research, 2018, 79, 234-238.	2.9	2
20	Samidorphan, an opioid receptor antagonist, attenuates drug-induced increases in extracellular dopamine concentrations and drug self-administration in male Wistar rats. Pharmacology Biochemistry and Behavior, 2021, 204, 173157.	2.9	2
21	Utility of Intracranial Self-Stimulation in the Assessment of the Abuse Liability of New Pharmaceuticals. , 2015, , 197-213.		0